3,10-dihydroxy-2-naphthacene Carboxamide Or Derivative (e.g., Tetracycline, Etc.) Doai Patents (Class 514/152)
-
Patent number: 9211296Abstract: This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.Type: GrantFiled: August 27, 2013Date of Patent: December 15, 2015Assignee: The Trustees of the University of PennsylvaniaInventor: Robert P. Ricciardi
-
Patent number: 9084802Abstract: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.Type: GrantFiled: March 11, 2014Date of Patent: July 21, 2015Assignee: REMPEX PHARMACEUTICALS, INC.Inventors: David C. Griffith, Serge Boyer, Scott Hecker, Michael N. Dudley
-
Patent number: 9080012Abstract: The instant disclosure describes a ring opening polymerization (ROP) of cyclic monomer components using a nucleophilic transesterification catalyst system in a neat, single pot reaction to obtain homopolymers and copolymers.Type: GrantFiled: July 10, 2013Date of Patent: July 14, 2015Assignee: Xerox CorporationInventors: Valerie M Farrugia, Andrew J Myles, Karen A Moffat, Jordan H Wosnick
-
SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS
Publication number: 20150148317Abstract: A drug delivery system is provided for treatment of oxidative stress. The drug delivery system can include a therapeutic agent and a matrix. The therapeutic agent can include an antioxidant or steroid. The matrix can include a hydrogel, particle, microparticle, or nanoparticle. A method of treating injury, including peripheral nerve injury or spinal cord injury, is also provided. The method includes injecting the drug delivery system at the site of injury.Type: ApplicationFiled: November 26, 2014Publication date: May 28, 2015Applicants: InVivo Therapeutics Corporation, Massachusetts Institute of TechnologyInventors: Christopher D. Pritchard, Robert S. Langer, Francis M. Reynolds, Eric J. Woodard -
Publication number: 20150141350Abstract: A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer.Type: ApplicationFiled: September 4, 2014Publication date: May 21, 2015Inventors: Rangaramanujam M. Kannan, Sujatha Kannan, Roberto Romero, Raghavendra S. Navath, Hui Dai, Anupa R. Menjoge
-
Publication number: 20150141381Abstract: Methods and compounds for treating diseases with tetracycline compounds having a target therapeutic activity are described.Type: ApplicationFiled: May 22, 2014Publication date: May 21, 2015Applicant: Paratek Pharmaceuticals, Inc.Inventors: Stuart B. Levy, Michael P. Draper, Mark L. Nelson, Graham Jones
-
Publication number: 20150139946Abstract: Provided is a method for monitoring a gene mutation associated with a cancer in a patient over time. Also provided is a method of selecting and/or applying treatment or therapy for a subject.Type: ApplicationFiled: October 19, 2014Publication date: May 21, 2015Inventors: Mark G. Erlander, Karena Kosco, Cecile Rose Vibat
-
Publication number: 20150140073Abstract: Drug delivery compositions are disclosed that include multimolecular assemblies that have heparosan polymer(s) attached thereto and therapeutic(s) (and/or potential therapeutic(s)) entrapped, carried, or otherwise bound in the multimolecular assemblies. Methods for producing and using the drug delivery compositions are also disclosed.Type: ApplicationFiled: January 28, 2015Publication date: May 21, 2015Inventor: Paul L. DeAngelis
-
Publication number: 20150132343Abstract: A method of treating a patient, comprising administering at least one antibiotic, e.g., doxycycline and ciprofloxacin, sufficient to substantially treat an intracellular bacterial organism present in at least erythrocytes, e.g., over a course of at least two weeks; and subsequently administering at least one immunostimulant, e.g., which directly or indirectly increases levels of immunostimulatory cytokines in the patient, and at least one antioxidant, e.g., glutathione, to effectively treat a coinfection of the patient with a virus. The intracellular bacterial organism may be a rickettsiales-like organism, and the virus may be HIV.Type: ApplicationFiled: November 10, 2014Publication date: May 14, 2015Inventor: Luc Montagnier
-
Publication number: 20150126435Abstract: Disclosed are primers, probes, and single nucleotide polymorphisms (SNP) specific to a distinct subclones of the E. coli sequence type 131 (ST131). Also disclosed are methods and assay kits useful in detecting the presence of the distinct subtype of E. coli and methods of treating a subject suffering from an infection from a subclone of ST131.Type: ApplicationFiled: July 2, 2013Publication date: May 7, 2015Inventors: Lance B. Price, Evgueni V. Sokurenko, James R. Johnson
-
Publication number: 20150125496Abstract: The present application provides a dosage form and related methods for making the dosage form. The dosage form generally comprises a hydrophilic active ingredient, a plurality of solid, porous microcarriers, each having a hydrophobic surface, an optional hydrophobic encapsulant, and a hydrophilic delivery agent, wherein (i) the hydrophilic active ingredient is associated with the plurality of solid, porous microcarriers, (ii) the plurality of solid, porous microcarriers is encapsulated by the hydrophobic encapsulant, and (iii) the hydrophilic delivery agent is physically separated from a majority of the hydrophilic active ingredient by a boundary between the hydrophilic delivery agent and the hydrophobic encapsulant. In some embodiments, the dosage form is for topical application. In some additional embodiments, the plurality of solid, porous microcarriers is formed by modifying the microcarriers to increase their hydrophobicity.Type: ApplicationFiled: November 4, 2014Publication date: May 7, 2015Inventor: Akira Yamamoto
-
Publication number: 20150110849Abstract: An antimicrobial accessory may include a pressure sensitive adhesive and an antimicrobial mixed in the pressure sensitive adhesive. In some examples, an antimicrobial accessory may include at least one first domain comprising a pressure sensitive adhesive and a first antimicrobial and at least one second domain including a second polymer and a second antimicrobial. The antimicrobial accessory may be configured to be attached to a housing of an implantable medical device (IMD).Type: ApplicationFiled: December 23, 2014Publication date: April 23, 2015Inventors: Kenneth E. COBIAN, Genevieve L. GALLAGHER, Peter M. SEILER, Kiem H. DANG, Michael S. HEMENWAY, Zhongping C. YANG, James L. SCHULD, Tico BLUMENTHAL
-
Publication number: 20150111834Abstract: The disclosure provides a recipe for in-situ gel, formed by dissolving at least one polymer and at least one gel prevention agent in a polar solvent to form a solution and placing the solution in a condition for in-situ forming gels. The disclosure also provides an implant and a drug delivery system formed by the recipe.Type: ApplicationFiled: September 17, 2014Publication date: April 23, 2015Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Felice CHENG, Maggie J.M. LU, Yi-Ju KO, Min-Ying LIN, Shuen-Hsiang CHOU
-
Patent number: 9012433Abstract: The present invention pertains to tetracycline compounds of formula (VIIa): R5*, R5*?, R7r*, and R9m* are defined herein. These tetracycline compounds can be used to treat tetracycline compound-responsive states, such as multiple sclerosis and rheumatoid arthritis.Type: GrantFiled: November 27, 2012Date of Patent: April 21, 2015Assignee: Paratek Pharmaceuticals, Inc.Inventors: Paul Abato, Todd Bowser
-
Publication number: 20150105355Abstract: The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: February 10, 2014Publication date: April 16, 2015Applicant: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Kwasi Ohemeng
-
Publication number: 20150104505Abstract: Pharmaceutical compositions in unit dose form comprising a hard or soft capsule containing a fill consisting of one or more inert ingredients, and one or more coatings on the capsule, wherein at least one coating comprises at least one active pharmaceutical ingredient.Type: ApplicationFiled: September 30, 2014Publication date: April 16, 2015Inventors: Manish S. SHAH, Ray J. DiFalco
-
Publication number: 20150098995Abstract: A process for producing a compressed solid dosage form containing an active ingredient. The process includes a step of preparing core elements containing the active ingredient. Optionally the core elements are coated with a pharmaceutically acceptable coating layer to form coated pellets. The core elements or pellets are treated with an anti-static agent and compressed with suitable excipients to form the compressed solid dosage form. Particular anti-static agents are starch, microcrystalline cellulose, kaolin, bentonite, silicates, silicon dioxide, cellulose, stearic acid, sodium stearyl fumarate and glyceryl behenate.Type: ApplicationFiled: May 5, 2014Publication date: April 9, 2015Inventor: Stefan Lukas
-
Publication number: 20150094282Abstract: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.Type: ApplicationFiled: December 5, 2014Publication date: April 2, 2015Inventors: David C. Griffith, Serge Boyer, Scott Hecker, Michael N. Dudley
-
Patent number: 8992896Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.Type: GrantFiled: August 27, 2014Date of Patent: March 31, 2015Assignee: Foamix Pharmaceuticals Ltd.Inventors: Dov Tamarkin, Elana Gazal, Irakliy Papiashvili, Yohan Hazot, David Schuz, Rita Keynan
-
Publication number: 20150080324Abstract: The present invention relates to antimalarial compounds and their use against protozoa of the genus Plasmodium, including drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.Type: ApplicationFiled: November 25, 2014Publication date: March 19, 2015Inventors: Gavin David Heffernan, David Penman Jacobus, Guy Alan Schiehser, Hong-Ming Shieh, Wenyi Zhao
-
Publication number: 20150071981Abstract: The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.Type: ApplicationFiled: October 26, 2014Publication date: March 12, 2015Inventor: Noam EMANUEL
-
Publication number: 20150056149Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.Type: ApplicationFiled: August 27, 2014Publication date: February 26, 2015Inventors: Dov Tamarkin, Elana Gazal, Irakliy Papiashvili, Yohan Hazot, David Schuz, Rita Keynan
-
Publication number: 20150057254Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.Type: ApplicationFiled: March 19, 2014Publication date: February 26, 2015Applicant: Supernus Pharmaceuticals, Inc.Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
-
Publication number: 20150050340Abstract: The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.Type: ApplicationFiled: October 26, 2014Publication date: February 19, 2015Inventor: Noam EMANUEL
-
Publication number: 20150045329Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: May 19, 2014Publication date: February 12, 2015Applicant: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Kwasi Ohemeng, Paul Abato, Victor Amoo, Haregewein Assefa, Joel Berniac, Beena Bhatia, Todd Bowser, Jackson Chen, Mark Grier, Laura Honeyman, Mohamed Y. Ismail, Oak K. Kim, Jude Mathews, Rachid Mechiche
-
Publication number: 20150044297Abstract: The invention relates to a novel galenical system for taste masking, protecting an active substance, in particular in an acid medium, modulating releasing properties, masking mucous irritability and toxicity of certain active substances, for preparing aqueous forms which have a masked taste, are stable and pH independent. Said invention also relates, in particular to a galenical system which is embodied in the form of lipidic solid particles and strictly hydrophobic and devoid of water, surface active agents, emulsifiers, solvent traces and which is characterized in that it comprises at least one type of hydrophobic wax and at least one type of fatty non-neutralised acid.Type: ApplicationFiled: October 27, 2014Publication date: February 12, 2015Inventors: Karim Ioualalen, Rose-Anne Raynal
-
Publication number: 20150038851Abstract: Provided herein are methods of diagnosing meibomian gland dysfunction (MGD), determining the severity of meibomian gland dysfunction in a subject, evaluating efficacy of treatment of MGD in a subject, selecting a subject for treatment of MGD, and selecting a subject for participation in a clinical study.Type: ApplicationFiled: February 21, 2013Publication date: February 5, 2015Inventors: Pedram Hamrah, Yureeda Qazi
-
Patent number: 8945623Abstract: The invention provides compositions, kits, and methods for treatment of neuronal injury. In one embodiment, the composition comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant.Type: GrantFiled: May 3, 2006Date of Patent: February 3, 2015Assignee: Warsaw Orthopedic, Inc.Inventors: Josee Roy, William F. McKay, Jeffrey C. Marx
-
Patent number: 8946196Abstract: Methods for the synthesis and purification of 9-amino alkyl tetracycline compounds are described.Type: GrantFiled: September 30, 2013Date of Patent: February 3, 2015Assignee: Paratek Pharmaceuticals, Inc.Inventors: Sean M. Johnston, Tadeusz Warchol
-
Patent number: 8945516Abstract: A substantially surface active agent free composition which includes a hydrophobic solvent, and/or a petrolatum, a paraffin wax and/or a fatty alcohol, a fatty acid and/or a wax and/or shea butter, with and without a propellant. A substantially surface active agent free composition, further comprising, a tetracycline antibiotic, or a vitamin D derivative, or one or more other active agents. A method of treatment using a substantially surface active agent free composition.Type: GrantFiled: October 1, 2010Date of Patent: February 3, 2015Assignee: Foamix Pharmaceuticals Ltd.Inventors: Dov Tamarkin, Elana Gazal, Yohan Hazot, David Schuz, Rita Keynan, Nukri Papiashvili
-
Publication number: 20150025025Abstract: An immuno-modulating composition including an organic compound and a metal chelator or a metal ion. Also disclosed is a method for treating a disease or condition in man and animals with the composition. Further, a method for delivering a growth factor or a homeostasis-maintaining factor to its receptor is provided.Type: ApplicationFiled: July 19, 2013Publication date: January 22, 2015Inventor: Ricky McCullough
-
Publication number: 20150023975Abstract: Matrix metalloproteases (MMPs) play many important roles in normal and pathological remodeling processes including atherothrombotic disease, inflammation, angiogenesis and cancer. This invention relates to the activation of protease-activated receptor-1 (PAR-1) by endogenous platelet MMP-1 collagenase on the surface of platelets. Exposure of platelets to fibrillar collagen converts the surface-bound pro-MMP-1 zymogen to active MMP-1, which promotes aggregation through PAR-1. MMP-1 is shown to cleave the PAR-1 extracellular domain at a novel site, which then strongly activates Rho-GTP signaling pathways, cell shape change and motility, and MAPK signaling. Blockade of MMP-PAR1 suppresses thrombogenesis under arterial flow conditions and inhibited thrombosis in animals. These studies provide a link between matrix-dependent activation of metalloproteases and platelet-G protein signaling and identify MMP-1/PAR-1 as a new target for the treatment and prevention of arterial thrombosis and other thrombotic diseases.Type: ApplicationFiled: August 14, 2014Publication date: January 22, 2015Inventors: Athan Kuliopulos, Georgios Koukos
-
Patent number: 8936795Abstract: A liquid embolic material may include a mixture of a first solution comprising between about 1.2% and about 2.5% weight per volume (w/v) carboxymethyl chitosan (CCN) in a first solvent and a second solution comprising between about 1.2% and about 2.5% w/v oxidized carboxymethyl cellulose (OCMC) in a second solvent. The liquid embolic material may be used to embolize a targeted embolization location by mixing the first solution and the second solution to form a liquid embolic material (or hydrogel precursor material), introducing the hydrogel precursor material to a targeted embolization location within a body of a patient, and allowing the CCN and the OCMC to react to form the hydrogel material and embolize the targeted embolization location.Type: GrantFiled: December 19, 2012Date of Patent: January 20, 2015Assignee: Regents of the University of MinnesotaInventors: Jafar Golzarian, Lihui Weng
-
Publication number: 20150004216Abstract: A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured.Type: ApplicationFiled: September 19, 2014Publication date: January 1, 2015Inventor: Robert Steven Davidson
-
Publication number: 20140377347Abstract: The present invention relates to an in-situ multilayered tablet comprising at least one polymer layers and at least one drug layers wherein the said layers are physically separated from each other. After coming in contact with biological and/or aqueous fluids at least one of the polymer layers rapidly swells and sticks to one or more drug layers to form an in-situ multilayered tablet. Further, the polymer layer may optionally comprise a drug. Furthermore, the present invention relates to the processes for preparing said in-situ multilayered tablets.Type: ApplicationFiled: January 23, 2013Publication date: December 25, 2014Applicant: RANBAXY LABORATORIES LIMITEDInventors: Kumaravel Vivek, Anuj Kumar Fanda, Murali Krishna, Ravish Kumar Sharma, Kanwarpreet Singh Bakshi, Romi Barat Singh, Ajay Kumar Singla
-
Patent number: 8911765Abstract: A biodegradable, flexible covering for a breast implant is provided which comprises one or more biodegradable polymer layers dimensioned and shaped to cover at least a portion of the breast implant. The implant can be inserted into an opening of the covering immediately prior to surgery, but alternate configurations and times of insertion are contemplated as well as open or sheet type devices. The coverings can optionally contain one or more drugs for delivery at the surgical site, particularly for treating or preventing infection, pain, inflammation, capsular contracture, scarring or other complications associated with breast augmentation or breast reconstruction.Type: GrantFiled: March 28, 2008Date of Patent: December 16, 2014Assignee: Tyrx, Inc.Inventors: Arikha Moses, Satish Pulapura, Qing Ge, Sarita Nethula, Irene Shatova, Archana Rajaram
-
Patent number: 8911775Abstract: Disclosed is a pH-sensitive block copolymer that forms polyionic complex micelles. The block copolymer is prepared by copolymerization of (a) a polyethylene glycol compound, (b) a poly(amino acid) compound, and (c) a heterocyclic alkyl amine compound having the ability to induce the formation of ionic complexes. Further disclosed is a drug or protein carrier using the block copolymer.Type: GrantFiled: July 23, 2010Date of Patent: December 16, 2014Assignee: Sungkyunkwan University Foundation for CorporateInventors: Doo Sung Lee, Bong Sup Kim, Jung Hee Lee, Guanghui Gao
-
Patent number: 8906887Abstract: The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.Type: GrantFiled: August 7, 2009Date of Patent: December 9, 2014Assignee: Tetraphase Pharmaceuticals, Inc.Inventors: Jingye Zhou, Xiao-Yi Xiao, Louis Plamondon, Diana Katharine Hunt, Roger B. Clark, Robert B. Zahler
-
Publication number: 20140349977Abstract: Methods for determining if a patient has, or is at risk of having, and autism spectrum disorder by detecting epigenetic changes in the genome of the patient. For example, a method can comprise determining the methylation status of one or more genes in a blood sample.Type: ApplicationFiled: October 12, 2012Publication date: November 27, 2014Applicant: ZYMO RESEARCH CORPORATIONInventors: Xueguang Sun, Xiyu Jia
-
Publication number: 20140349938Abstract: The invention features methods of diagnosing a subject as having, or at risk of developing ALS by determining the frequency of Gems in cells obtained from the subject. These methods include diagnosing the severity or monitoring the progression of ALS by determining the Gem frequency in a subject. Also, the invention features methods of identifying compounds useful for the treatment of ALS as well as methods for the treatment of ALS.Type: ApplicationFiled: June 1, 2012Publication date: November 27, 2014Applicant: President and Fellows of Harvard CollegeInventors: Robin Reed, Shi Chen, Yong Yu, Tomohiro Yamazaki
-
Patent number: 8895047Abstract: Implantable catheters are provided which comprise an antimicrobial agent incorporated in a coating or bulk distributed, in combination with a fibrinolytic agent incorporated in a top coating.Type: GrantFiled: May 21, 2008Date of Patent: November 25, 2014Assignee: Arrow International, Inc.Inventors: Nisha Gupta, Joel Rosenblatt, Daniel J. Spangler
-
Publication number: 20140343020Abstract: A method for modulating RNA with tetracycline compounds is described.Type: ApplicationFiled: March 7, 2014Publication date: November 20, 2014Applicant: PARATEK PHARMACEUTICALS, INCInventors: Stuart B. Levy, Michael P. Draper, Mark L. Nelson, Graham Jones
-
Publication number: 20140335047Abstract: The present invention provides a particulate delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload molecule and a payload trapping molecule. The invention further provides methods of making and methods of using the particulate delivery system.Type: ApplicationFiled: November 6, 2013Publication date: November 13, 2014Applicant: UNIVERSITY OF MASSACHUSETTSInventor: Gary R. OSTROFF
-
Publication number: 20140323391Abstract: Disclosed herein are biomarkers useful for identifying and/or classifying bacterial infections in a subject.Type: ApplicationFiled: March 15, 2014Publication date: October 30, 2014Applicant: Duke UniversityInventors: Ephraim Tsalik, Vance Fowler, Christopher W. Woods, Joseph E. Lucas, Geoffrey S. Ginsburg, Sun Hee Ahn
-
Patent number: 8871184Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents; and the amount of viscosity modifying agents can optionally be reduced by at least an amount by weight that would have increased the viscosity of the carrier without the tetracycline antibiotic by at least 30%; wherein the tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracyclineType: GrantFiled: October 1, 2010Date of Patent: October 28, 2014Assignee: Foamix Ltd.Inventors: Dov Tamarkin, Elana Gazal, Yohan Hazot, David Schuz, Rita Keynan, Nukri Papiashvili
-
Publication number: 20140314798Abstract: The present invention concerns methods and compositions for treatment and determination of the presence or likelihood of an individual to have an ocular surface inflammation. In specific embodiments, a sample from the individual is assayed for the expression level of three or more genes, including IL-6, MMP3, MMP9, IFNy, SPRR-IA, HLA-DRA, MUC5AC, K7, and IL17A. Treatment is provided to an individual with ocular surface inflammation based upon the gene analysis.Type: ApplicationFiled: October 19, 2012Publication date: October 23, 2014Inventors: Stephen C. Pflugfelder, Cintia S. De Paiva, Rosa M. Corrales Herran, De-Quan Li
-
Patent number: 8865686Abstract: The instant invention is directed towards tetracycline compositions, and methods of inhibiting Tdp1 activity, and methods of treating Tdp1-associated disorders.Type: GrantFiled: September 29, 2008Date of Patent: October 21, 2014Assignee: The United States of America, as Represented by the Secretary, Dept. of Health and Human ServicesInventors: Yves Pommier, Laurent Thibaut, Christophe Marchand
-
Patent number: 8865139Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.Type: GrantFiled: July 9, 2014Date of Patent: October 21, 2014Assignee: Foamix Pharmaceuticals Ltd.Inventors: Dov Tamarkin, Elana Gazal, Irakliy Papiashvili, Yohan Hazot, David Schuz, Rita Keynan
-
Publication number: 20140309185Abstract: This document relates to inhibitors of G protein coupled receptor 6 kinase (GRK6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.Type: ApplicationFiled: October 26, 2012Publication date: October 16, 2014Inventors: Alexander Keith Stewart, Artem Plekhov, Robert Greenhouse
-
Publication number: 20140309199Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: June 27, 2014Publication date: October 16, 2014Inventors: Mark L. Nelson, Roger Frechette, Mohamed Y. Ismail, Laura Honeyman, Todd Bowser, Beena Bhatia